NFLUENCE OF CYP4F2*3 ON RESPONSE TO CLOPIDOGREL IN PATIENTS WITH ACUTE CORONARY SYNDROME

NFLUENCE OF CYP4F2*3 ON RESPONSE TO CLOPIDOGREL IN PATIENTS WITH ACUTE CORONARY SYNDROME

Background. Carriership of CYP4F2*3 (rs2108622, Val433Met) allelic variant can affect antiplatelet effect of clopidogrel, thus changing efficacy and safety of its standard dose.Aim. To study the impact of carriership of at least one CYP4F2*3 allele on the risk of resistance to clopidogrel in patient...

Full description

Bibliographic Details
Main Authors:	K. B. Mirzaev, O. D. Konova, E. A. Grishina, K. A. Ryzhikova, Zh. A. Sozaeva, D. A. Andreev, M. Y. Gilyarov, D. A. Sychev
Format:	Article
Language:	English
Published:	Столичная издательская компания 2018-03-01
Series:	Рациональная фармакотерапия в кардиологии
Subjects:	cyp4f2 acute coronary syndrome pharmacogenetics clopidorgel p2y12-receptor blockers.
Online Access:	https://www.rpcardio.online/jour/article/view/1617

Similar Items

INFLUENCE OF THE CYP3A4 ISOENZYME METABOLIC ACTIVITY AND CYP2C19 GENE POLYMORPHISMS ON CLOPIDOGREL ANTIPLATELET EFFECT IN PATIENTS WITH ACUTE CORONARY SYNDROME UNDERGOING PERCUTANEOUS CORONARY INTERVENTION
by: K. B. Mirzaev, et al.
Published: (2015-09-01)

THE SIGNIFICANCE OF PHARMACOGENETIC CYP2C19 TESTING FOR PERSONALIZATION OF THE ANTIPLATELET THERAPY IN CARDIOLOGY PRACTICE
by: K. B. Mirzaev, et al.
Published: (2015-09-01)

Pharmacogenetic and Clinical Predictors of Clopidogrel Insufficiency in a Patient with Atherosclerosis Obliterans of the Lower Extremities: Clinical Case
by: M. A. Andreyanova, et al.
Published: (2018-11-01)

INFLUENCE OF THE CYP3A4 ISOENZYME METABOLIC ACTIVITY AND CYP2C19 GENE POLYMORPHISMS ON CLOPIDOGREL ANTIPLATELET EFFECT IN PATIENTS WITH ACUTE CORONARY SYNDROME UNDERGOING PERCUTANEOUS CORONARY INTERVENTION
by: K. B. Mirzaev, et al.
Published: (2015-09-01)

CLOPIDOGREL PHARMACOGENETICS
by: A. N. Meshkov
Published: (2016-01-01)

CYP2C19 genetic variation and individualized clopidogrel prescription in a cardiology clinic
by: Seyed abbas Mirabbasi, et al.
Published: (2017-07-01)

GENETICS OF CLOPIDOGREL RESISTANCE: RECENT DATA
by: K. B. Mirzaev, et al.
Published: (2015-10-01)

Antihypertensive Effect Of Amlodipine In Co-Administration With Omeprazole In Patients With Hypertension And Acid-Related Disorders: Cytochrome P450-Associated Aspects
by: Dorofeeva MN, et al.
Published: (2019-11-01)

Structure of the distribution of genetic determinants of the efficacy and safety of non-steroidal anti-inflammatory drugs in the Russian population: focus on CYP2C8, PTGS1 and PTGS2
by: N. P. Denisenko, et al.
Published: (2022-02-01)

Ticagrelor is more effective than clopidogrel in carrier of nonfunctional CYP2C19 allele who has diabetes and acute coronary syndrome - case report and literature review
by: Rahel Tekeste, et al.
Published: (2022-04-01)

Evaluation of the association of polymorphisms of the CYP2C8 gene with the efficacy and safety of ketorolac in patients with postoperative pain syndrome
by: Andranik A. Muradian, et al.
Published: (2022-06-01)

Effect of polymorphisms in CYP3A4*22 (rs35599367) C>T, CYP3A5*3 (rs776746) A>G, ABCB1 (rs4148738) C>T and ABCB1 (rs1045642) C>T genes on apixaban anticoagulation: pilot study results
by: I. N. Sychev, et al.
Published: (2021-04-01)

Genetic polymorphism of clopidogrel metabolism related gene CYP2C19 gene in Chinese from Foshan area of Guangdong Province
by: Xiao-wen Yuan, et al.
Published: (2022-12-01)

CYP3A and CYP2C19 activity in urine in relation to CYP3A4, CYP3A5, and CYP2C19 polymorphisms in Russian peptic ulcer patients taking omeprazole
by: Denisenko NP, et al.
Published: (2018-06-01)

CYP2C19 Genotype‐Guided Antiplatelet Therapy After Percutaneous Coronary Intervention in Diverse Clinical Settings
by: Amber L. Beitelshees, et al.
Published: (2022-02-01)

CYP2C8, PTGS-1, 2 gene polymorphisms prevalence associated with sensitivity to non-steroidal anti-inflammatory drugs among North Caucasus ethnic groups
by: Sherzod P. Abdullaev, et al.
Published: (2021-11-01)

Prevalence of CYP2C19*2 and CYP2C19*3 Allelic Variants and Clopidogrel Use in Patients with Cardiovascular Disease in Trinidad & Tobago
by: Daniele Jones, et al.
Published: (2024-01-01)

Factors affecting the development of adverse drug reactions to β-blockers in hospitalized cardiac patient population
by: Mugo&scaron;a S, et al.
Published: (2016-08-01)

The Effect of Polymorphisms in the CYP2D6 and CYP2C9 Genes on the Clinical Efficacy of Tramadol and Ketorolac When Using the Accelerated Recovery Protocol in Patients With Uncomplicated Acute Calculous Cholecystitis Who Underwent Cholecystectomy
by: A. A. Muradyan, et al.
Published: (2020-10-01)

CYP2C19*2 Polymorphism Is Associated with Impaired Oral Clearance of Gliclazide in Healthy Chinese
by: Chow E, et al.
Published: (2020-01-01)

THE SIGNIFICANCE OF PHARMACOGENETIC CYP2C19 TESTING FOR PERSONALIZATION OF THE ANTIPLATELET THERAPY IN CARDIOLOGY PRACTICE
by: K. B. Mirzaev, et al.
Published: (2015-09-01)

PREVALENCE OF POLYMORPHOUS LOCUS 681G>A OF CYP2C19 GENE IN RUSSIAN POPULATION
by: T. A. Bairova, et al.
Published: (2014-11-01)

Genetic polymorphisms of CYP2B6*6, CYP2C8*3 and CYP2D6*4 in vivax malaria patients from Brazilian Amazon
by: José Pereira de Moura Neto, et al.
Published: (2023-11-01)

Urine metabolic ratio of omeprazole in relation to CYP2C19 polymorphisms in Russian peptic ulcer patients
by: Denisenko NP, et al.
Published: (2017-09-01)

Analysis of CYP2C9*2, CYP2C19*2, and CYP2D6*4 polymorphisms in patients with type 2 diabetes mellitus
by: Sabina Semiz, et al.
Published: (2010-11-01)

CYP2C19 PHARMACOGENETIC TESTING FOR PERSONALIZATION OF ANTIPLATELET THERAPY IN PATIENTS WITH ACUTE CORONARY SYNDROME IN ROUTINE CLINICAL PRACTICE
by: A. I. Akhmetova, et al.
Published: (2017-12-01)

The prevalence of CYP2D6*10 (100C>T, rs1065852) gene polymorphism in Russian patients with epilepsy (North-Western and Siberian Districts)
by: N. A. Sivakova, et al.
Published: (2019-12-01)

Genetic analysis of the equine orthologues for human CYP2D6: unraveling the complexity of the CYP2D family in horses
by: Giada Scantamburlo, et al.
Published: (2023-10-01)

CYP2D6 Predicts Plasma Donepezil Concentrations in a Cohort of Thai Patients with Mild to Moderate Dementia
by: Chamnanphon M, et al.
Published: (2020-11-01)

Association of CYP3A4*1B, CYP3A4*22 and CYP3A5*3 polymorphisms carriage with efficacy and safety of tamsulosin in patients with benign prostatic hyperplasia
by: Sh. P. Abdullaev, et al.
Published: (2024-05-01)

Influence of CYP2D6, CYP2C19 and CYP3A5 polymorphisms on plasma levels of tamoxifen metabolites in Algerian women with ER+ breast cancer
by: Amira Boucenna, et al.
Published: (2022-08-01)

MDMA, methamphetamine, and CYP2D6 pharmacogenetics: what is clinically relevant?
by: Rafael eDe La Torre, et al.
Published: (2012-11-01)

An Investigational Study on the Role of <i>CYP2D6</i>, <i>CYP3A4</i> and <i>UGT</i>s Genetic Variation on Fesoterodine Pharmacokinetics in Young Healthy Volunteers
by: Andrea Rodríguez-Lopez, et al.
Published: (2024-09-01)

Co-Existence of CYP2C19*1/*2 and ABCB1c.3435 CT Genotype has a Potential Impact on Clinical Outcome in CAD Patients Treated with Clopidogrel
by: Nestorovska KA, et al.
Published: (2024-03-01)

Allelic diversity of the pharmacogene CYP2D6 in New Zealand Māori and Pacific peoples
by: Leonie M. Hitchman, et al.
Published: (2022-10-01)

The efficacy of clopidogrel in preventing recurrent cardiovascular events among Arab population carrying different CYP2C19 mutations: systematic review and meta-analysis
by: Abdullah N. Alkattan, et al.
Published: (2022-06-01)

Effects of CYP2D6 genetic polymorphisms on the efficacy and safety of fluvoxamine in patients with depressive disorder and comorbid alcohol use disorder
by: Zastrozhin MS, et al.
Published: (2018-06-01)

Genetic polymorphisms of CYP2C19 in ecuadorian population: An interethnic approach
by: Alba Alonso Llorente, et al.
Published: (2024-04-01)

Impact of CYP3A7, CYP2D6 and ABCC2/ABCC3 polymorphisms on tacrolimus steady state concentrations in Bulgarian kidney transplant recipients
by: Tsvetelin Lukanov, et al.
Published: (2022-12-01)

<i>CYP2C9</i> Polymorphism Influence in PK/PD Model of Naproxen and 6-O-Desmethylnaproxen in Oral Fluid
by: Gabriela Moraes Oliveira, et al.
Published: (2022-11-01)